1	Debe	deber	VMIP3S0	-	-	0-4	232(4)_ANS_clinical_caseMIR	SENT1	-	-
2	valorar	valorar	VMN0000	-	-	5-12	232(4)_ANS_clinical_caseMIR	SENT1	-	-
3	se	se	PP3CN000	-	-	12-14	232(4)_ANS_clinical_caseMIR	SENT1	-	-
4	el	el	DA0MS0	-	-	15-17	232(4)_ANS_clinical_caseMIR	SENT1	-	-
5	tratamiento	tratamiento	NCMS000	C1273870#C0087111	procedimiento#r√©gimen/tratamiento	18-29	232(4)_ANS_clinical_caseMIR	SENT1	-	-
6	con	con	SPS00	C0332287	atributo	30-33	232(4)_ANS_clinical_caseMIR	SENT1	-	-
7	etanercept	etanercept	NC00SC0	C0717758#C0018100	producto#sustancia	34-44	232(4)_ANS_clinical_caseMIR	SENT1	B-Grp_Medicamento	-
8	(	(	Fpa	-	-	45-46	232(4)_ANS_clinical_caseMIR	SENT1	-	-
9	un	un		C0205447_1	calificador_1	46-48	232(4)_ANS_clinical_caseMIR	SENT1	-	-
10	anticuerpo	anticuerpo	NCMS000	C0003241	sustancia	49-59	232(4)_ANS_clinical_caseMIR	SENT1	-	-
11	anti-TNFa	anti-tnfa	NCFS000	-	-	60-69	232(4)_ANS_clinical_caseMIR	SENT1	-	-
12	)	)	Fpt	-	-	69-70	232(4)_ANS_clinical_caseMIR	SENT1	-	-
13	.	.	Fp	-	-	71-72	232(4)_ANS_clinical_caseMIR	SENT1	-	-

